Ortho Clinical Diagnostics Holdings plc is a diagnostics & research business based in the US. Ortho Clinical Diagnostics shares (OCDX) are listed on the NASDAQ and all prices are listed in US Dollars. Ortho Clinical Diagnostics employs 4,500 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Guided Investing
Our top pick for
Large Accounts
| Latest market close | $19.06 |
|---|---|
| 52-week range | $15.14 - $21.82 |
| 50-day moving average | $19.71 |
| 200-day moving average | $18.56 |
| Wall St. target price | $24.82 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | N/A |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $19.06 from 2021-10-25
| 1 week (2021-10-19) | -5.17% |
|---|---|
| 1 month (2021-09-23) | 1.82% |
| 3 months (2021-07-26) | -10.64% |
| 6 months (2021-04-23) | -5.60% |
| 1 year (2020-10-22) | N/A |
|---|---|
| 2 years (2019-10-22) | N/A |
| 3 years (2018-10-22) | N/A |
| 5 years (2016-10-22) | N/A |
Valuing Ortho Clinical Diagnostics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ortho Clinical Diagnostics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ortho Clinical Diagnostics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $438.9 million.
The EBITDA is a measure of a Ortho Clinical Diagnostics's overall financial performance and is widely used to measure a its profitability.
To put Ortho Clinical Diagnostics's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $1.9 billion |
|---|---|
| Operating margin TTM | 8.34% |
| Gross profit TTM | $880.4 million |
| Return on assets TTM | 1.97% |
| Return on equity TTM | 0% |
| Profit margin | -8.03% |
| Book value | N/A |
| Market capitalisation | $4.7 billion |
TTM: trailing 12 months
There are currently 2.7 million Ortho Clinical Diagnostics shares held short by investors – that's known as Ortho Clinical Diagnostics's "short interest". This figure is 10.4% up from 2.4 million last month.
There are a few different ways that this level of interest in shorting Ortho Clinical Diagnostics shares can be evaluated.
Ortho Clinical Diagnostics's "short interest ratio" (SIR) is the quantity of Ortho Clinical Diagnostics shares currently shorted divided by the average quantity of Ortho Clinical Diagnostics shares traded daily (recently around 869855.22875817). Ortho Clinical Diagnostics's SIR currently stands at 3.06. In other words for every 100,000 Ortho Clinical Diagnostics shares traded daily on the market, roughly 3060 shares are currently held short.
To gain some more context, you can compare Ortho Clinical Diagnostics's short interest ratio against those of similar companies.
However Ortho Clinical Diagnostics's short interest can also be evaluated against the total number of Ortho Clinical Diagnostics shares, or, against the total number of tradable Ortho Clinical Diagnostics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ortho Clinical Diagnostics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Ortho Clinical Diagnostics shares in existence, roughly 10 shares are currently held short) or 0.0294% of the tradable shares (for every 100,000 tradable Ortho Clinical Diagnostics shares, roughly 29 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ortho Clinical Diagnostics.
Find out more about how you can short Ortho Clinical Diagnostics stock.
We're not expecting Ortho Clinical Diagnostics to pay a dividend over the next 12 months.
Ortho Clinical Diagnostics Holdings plc engages in the vitro diagnostics business worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company also engages in contract manufacturing activities; and provides orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. The company was founded in 1939 and is headquartered in Raritan, New Jersey. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.